← Sanofi SA overview

Sanofi SA vs Replimune: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sanofi SA (SAN.PA)

Q3 2026
▲2▼2

Sanofi Q3: strong sales and new approvals offset by pipeline setbacks

  • Strong sales and raised guidance Sanofi's Q2 sales rose 17.8% with Dupixent up 37.6% to €5.2bn, leading to raised full-year guidance. This shows the core business is performing well and supports the stock.

    This is a key positive driver for the quarter, showing strong financial performance.

  • New drug approvals and expanded alliance FDA approved subcutaneous Sarclisa Escena, EU approved MenQuadfi for infants, and Sanofi expanded its Regeneron alliance with $1bn upfront. These broaden the product portfolio and settle litigation.

    These are new positive developments that can drive future growth.

  • Pipeline setbacks and safety concerns Amlitelimab was halted for atopic dermatitis, and the infant RSV vaccine trial was permanently stopped after an infant death. These raise safety concerns and delay potential new revenue.

    These are significant negative events that weigh on sentiment and future prospects.

  • Competitive threats and lost revenue AbbVie, Moderna, Novartis, and AstraZeneca pose competitive threats to key products, and the Cheplapharm deal removes steady revenue. This pressures future sales and market share.

    Competition and revenue loss are important negative factors for the stock.

September 2026
▲2▼1

Sanofi's pipeline and partnership news reshape growth outlook

  • New drug sales surge 48.3% Sanofi's new and acquired drugs, like Altuviiio and Sarclisa, grew sales 48.3% to €1.3 billion in Q2. This shows the company is building new revenue sources beyond Dupixent, which supports the stock price.

    This is a key positive fundamental driver showing Sanofi's growth diversification.

  • Expanded Regeneron alliance Sanofi will pay $1 billion upfront and up to $7 billion in milestones to co-develop four new antibodies with Regeneron. This broadens Sanofi's pipeline and settles litigation, boosting investor confidence.

    This major partnership expansion is a new positive catalyst for Sanofi's future growth.

  • Competitive threats to key drugs Novartis's remibrutinib beat Sanofi's Aubagio in MS trials, and AstraZeneca's tozorakimab may reach more COPD patients than Dupixent. These rival drugs could erode Sanofi's sales in important markets.

    These competitive losses directly threaten Sanofi's existing product revenue.

  • Portfolio restructuring with Cheplapharm Sanofi is handing 20 mature medicines and three plants to Cheplapharm for a 26.4% stake. This simplifies the business but removes steady revenue, with no impact on 2026 guidance.

    This strategic divestment has ambiguous implications for Sanofi's future earnings.

Latest
▲2▼1

Sanofi's pipeline and partnership news reshape growth outlook

  • New drug sales surge 48.3% Sanofi's new and acquired drugs, like Altuviiio and Sarclisa, grew sales 48.3% to €1.3 billion in Q2. This shows the company is building new revenue sources beyond Dupixent, which supports the stock price.

    This is a key positive fundamental driver showing Sanofi's growth diversification.

  • Expanded Regeneron alliance Sanofi will pay $1 billion upfront and up to $7 billion in milestones to co-develop four new antibodies with Regeneron. This broadens Sanofi's pipeline and settles litigation, boosting investor confidence.

    This major partnership expansion is a new positive catalyst for Sanofi's future growth.

  • Competitive threats to key drugs Novartis's remibrutinib beat Sanofi's Aubagio in MS trials, and AstraZeneca's tozorakimab may reach more COPD patients than Dupixent. These rival drugs could erode Sanofi's sales in important markets.

    These competitive losses directly threaten Sanofi's existing product revenue.

  • Portfolio restructuring with Cheplapharm Sanofi is handing 20 mature medicines and three plants to Cheplapharm for a 26.4% stake. This simplifies the business but removes steady revenue, with no impact on 2026 guidance.

    This strategic divestment has ambiguous implications for Sanofi's future earnings.

August 2026
▲2▼2

Sanofi expands infant vaccine reach but faces pipeline and competition setbacks

  • EU approval of MenQuadfi for infants Sanofi won EU approval to use its MenQuadfi vaccine in infants as young as six weeks, opening a new market. This should boost vaccine sales and strengthen Sanofi's pediatric portfolio, supporting the stock price.

    This is a new regulatory win that directly expands Sanofi's vaccine market and revenue potential.

  • Novavax partnership advances with milestones Sanofi's partnership with Novavax is progressing, with a Phase 3 COVID/flu combo study planned and milestone payments ahead. Sanofi will lead commercial launches of Nuvaxovid, adding to its vaccine business and future revenue.

    This shows Sanofi's collaboration is moving forward, with potential milestone income and expanded commercial reach.

  • Permanent halt of infant RSV vaccine trial Sanofi permanently stopped its Phase 3 RSV vaccine trial in infants after an infant death, raising safety and regulatory concerns. This removes a potential future product and may hurt Sanofi's reputation in pediatric vaccines, weighing on the stock.

    This is a major pipeline setback with reputational and regulatory implications that could lower investor confidence.

  • Competition heats up from AbbVie and Moderna AbbVie is buying Apogee to get a drug that could rival Sanofi's top-selling Dupixent, while Moderna won FDA approval for the first mRNA flu shot, challenging Sanofi's flu vaccine franchise. Both threaten key Sanofi products.

    These are new competitive threats that could pressure Sanofi's sales in two major areas: immunology and flu vaccines.

▲2▼2

Sanofi expands infant vaccine reach but faces pipeline and competition setbacks

  • EU approval of MenQuadfi for infants Sanofi won EU approval to use its MenQuadfi vaccine in infants as young as six weeks, opening a new market. This should boost vaccine sales and strengthen Sanofi's pediatric portfolio, supporting the stock price.

    This is a new regulatory win that directly expands Sanofi's vaccine market and revenue potential.

  • Novavax partnership advances with milestones Sanofi's partnership with Novavax is progressing, with a Phase 3 COVID/flu combo study planned and milestone payments ahead. Sanofi will lead commercial launches of Nuvaxovid, adding to its vaccine business and future revenue.

    This shows Sanofi's collaboration is moving forward, with potential milestone income and expanded commercial reach.

  • Permanent halt of infant RSV vaccine trial Sanofi permanently stopped its Phase 3 RSV vaccine trial in infants after an infant death, raising safety and regulatory concerns. This removes a potential future product and may hurt Sanofi's reputation in pediatric vaccines, weighing on the stock.

    This is a major pipeline setback with reputational and regulatory implications that could lower investor confidence.

  • Competition heats up from AbbVie and Moderna AbbVie is buying Apogee to get a drug that could rival Sanofi's top-selling Dupixent, while Moderna won FDA approval for the first mRNA flu shot, challenging Sanofi's flu vaccine franchise. Both threaten key Sanofi products.

    These are new competitive threats that could pressure Sanofi's sales in two major areas: immunology and flu vaccines.

July 2026
▲3▼1

Sanofi Q2 Beat and New Approvals Offset Pipeline Setback

  • FDA approves subcutaneous Sarclisa Escena The FDA approved Sarclisa Escena, the first on-body injector cancer treatment, offering patients a more convenient option and expanding Sanofi's oncology portfolio. This approval supports future revenue growth and boosts investor confidence.

    This is a new regulatory approval that directly supports Sanofi's growth outlook.

  • Q2 results beat expectations, guidance raised Sanofi reported Q2 sales up 17.8%, raised full-year guidance, and saw Dupixent sales surge 37.6% to €5.2bn. Partner Regeneron also posted a strong quarter, reinforcing confidence in Sanofi's growth trajectory.

    Strong quarterly results and raised guidance are key positive drivers for the stock.

  • Nexviazyme meets all phase 3 endpoints Nexviazyme met all phase 3 endpoints in infant Pompe disease, potentially expanding its label and addressing a serious unmet need. This positive trial outcome supports future sales growth and strengthens Sanofi's rare disease franchise.

    A successful phase 3 trial is a new positive catalyst for Sanofi's pipeline.

  • Sanofi halts amlitelimab for atopic dermatitis Sanofi halted development of amlitelimab for atopic dermatitis due to insufficient efficacy and safety, removing a much-anticipated growth driver. This setback weighs on sentiment and raises questions about the pipeline's near-term potential.

    This pipeline failure is a significant negative event that impacts future growth prospects.

▲3▼1

Sanofi raises outlook on Dupixent surge, but pipeline setback weighs

  • Q2 earnings beat and raised 2026 guidance Sanofi reported Q2 sales up 17.8% and raised its 2026 outlook, with Dupixent sales jumping 37.6% to €5.2 billion. This strong performance and confident guidance signal accelerating growth, which should lift investor confidence and support a higher share price.

    This is the most significant new event, directly showing Sanofi's financial health and future prospects.

  • Amlitelimab development halted for atopic dermatitis Sanofi discontinued amlitelimab for moderate-to-severe atopic dermatitis, a key pipeline candidate, due to insufficient efficacy and safety data. This removes a potential growth driver and may hurt sentiment, as investors had high hopes for the drug in a large market.

    This is a major pipeline setback that could negatively impact future revenue expectations.

  • Dupixent partner Regeneron beats estimates Regeneron's strong quarterly results, driven by Dupixent sales up 38% to $6 billion, confirm robust demand for Sanofi's top-selling drug. As Sanofi records these sales, the beat reinforces confidence in Dupixent's growth trajectory and Sanofi's earnings power.

    This provides independent validation of Dupixent's blockbuster performance, a key value driver for Sanofi.

  • Aqemia AI collaboration expands with new target Sanofi expanded its AI-driven drug discovery partnership with Aqemia, nominating a new target and potentially paying up to $140 million in milestones. This strengthens Sanofi's early-stage pipeline and shows commitment to innovative technologies, which could yield future blockbuster drugs.

    This highlights Sanofi's investment in cutting-edge R&D, supporting long-term growth prospects.

▲3▼1

Sanofi pipeline wins and FDA nod offset cautious analyst view

  • FDA approves Sarclisa Escena on-body injector The FDA approved subcutaneous Sarclisa Escena for all multiple myeloma uses, the first anticancer treatment given via on-body injector. It cuts treatment time and infusion reactions, which can lift sales and strengthen Sanofi's cancer franchise.

    This is a new regulatory approval that expands a key product's use and could drive future revenue.

  • Nexviazyme hits all goals in infant Pompe disease trial Sanofi's Nexviazyme met all endpoints in a phase 3 study for infants with infantile-onset Pompe disease, supporting a US label extension filing later in 2026. Success in a rare disease with few options adds a new growth driver.

    Positive late-stage trial data for an existing drug opens a new patient population and revenue stream.

  • WAYRILZ positioned in fast-growing AIHA market A market report projects 14.4% annual growth for warm autoimmune hemolytic anemia treatments through 2036, with no approved therapies yet. Sanofi's WAYRILZ is a key late-stage candidate, giving it a large untapped opportunity if approved.

    Highlights a new market opportunity for a Sanofi pipeline drug, supporting long-term growth prospects.

  • UBS cautious on Sanofi within favored pharma sector UBS likes European pharma as a safer bet than AI but is more cautious on Sanofi, preferring AstraZeneca and Roche. This relative caution may steer some investor money away from Sanofi shares, limiting upside versus peers.

    Analyst preference can influence capital flows and relative stock performance.

Q2 2026
▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

June 2026
▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

Replimune Group Inc (REPL)

Q3 2026
▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

  • FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.

    This was the key regulatory catalyst that drove the stock's massive jump.

  • Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.

    This approval is a major milestone that transforms the company's business prospects.

  • Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.

    These investigations pose a legal overhang that could weigh on the stock.

  • Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.

    The offering dilutes current shareholders and can pressure the share price.

July 2026
▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

  • FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.

    This was the key regulatory catalyst that drove the stock's massive jump.

  • Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.

    This approval is a major milestone that transforms the company's business prospects.

  • Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.

    These investigations pose a legal overhang that could weigh on the stock.

  • Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.

    The offering dilutes current shareholders and can pressure the share price.

Latest
▲2▼2

FDA approves Replimune's first drug, then company raises $150M

  • FDA grants accelerated approval for Tudriqev The FDA granted accelerated approval to Replimune's Tudriqev combined with Opdivo for advanced melanoma, based on a 24.2% response rate. This is the company's first commercial product, turning it from a clinical-stage hopeful into a revenue-generating business and lifting the stock.

    This is the single biggest new event: approval validates the drug and opens a path to sales.

  • Securities fraud investigation expands to Pomerantz Pomerantz LLP opened an investigation into whether Replimune misled investors before the FDA's July 28 briefing documents questioned the RP1 data. This adds to earlier law firm probes, keeping a legal cloud over the stock and potentially weighing on the price.

    It is a new law firm joining the investigation, adding fresh negative pressure.

  • $150 million stock offering dilutes shareholders Replimune priced a $150 million stock sale at $12.06 per share, issuing about 9.7 million new shares. This raises cash to launch Tudriqev but dilutes existing investors' ownership, which typically pushes the stock down in the short term.

    It is a new financing event that directly affects share count and cash position.

  • FDA flexibility and biotech rally support Replimune The FDA signaled a more flexible approval approach for serious diseases, opening new pathways for Replimune and others. This supportive regulatory backdrop helped biotech stocks broadly and made RP1's eventual approval more likely, lifting sentiment around Replimune.

    It explains the favorable regulatory environment that helped Replimune's path to approval.

▲2▼1

FDA panel backs RP1, reversing prior briefing-document collapse

  • FDA advisory panel votes 10-3 in favor of RP1 An FDA advisory committee voted 10 to 3 that RP1's single-arm IGNYTE study results are evaluable and clinically meaningful for advanced melanoma. This removes the main regulatory doubt and makes approval by the August 2 target date far more likely, pushing the stock sharply higher.

    This is the core new event that flipped sentiment and drove the huge price jump.

  • Stock surges over 130% premarket, analyst upgrade Replimune shares soared more than 130% before the open and were up about 94-125% during the day after the panel vote. Wedbush upgraded the stock to outperform from neutral, a sign that professional investors now see the approval path as much clearer.

    Shows the market's immediate, large positive reaction and a key analyst endorsement.

  • Securities fraud investigations launched Two law firms, Kirby McInerney and Bragar Eagel & Squire, opened investigations into whether Replimune misled investors before the FDA's July 28 briefing documents called the RP1 study non-interpretable. No lawsuit has been filed yet, but this legal cloud could weigh on the stock.

    A real counterweight that could hurt the stock even after the positive panel vote.

© 2026 MarketIVWhy